Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Submission of Matters to a Vote of Security Holders

19

Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07

Submission of Matters to a Vote of Security Holders.
On June 15, 2017, Juno Therapeutics, Inc. (Juno) held its 2017
Annual Meeting of Stockholders (the Annual Meeting). At the
Annual Meeting, 79,477,735 shares of Junos common stock, or
approximately 74.91% of the total shares entitled to vote, were
represented. Stockholders voted on the following three proposals
at the Annual Meeting, each of which is described in more detail
in Junos definitive proxy statement filed with the United States
Securities and Exchange Commission on April 24, 2017 (the “Proxy
Statement”):
Proposal OneElection of Directors
The following nominees were elected as Class III directors to
serve until the 2020 annual meeting of stockholders or until
their respective successors are duly elected and qualified. The
voting results for each nominee were as follows:
For
Withhold
Broker Non-Votes
Thomas O. Daniel, M.D.
58,567,388
4,074,713
16,835,634
Rupert Vessey, BM BCh, DPhil
59,950,006
2,692,095
16,835,634
Mary Agnes Wilderotter
57,590,525
5,051,576
16,835,634
Proposal TwoAdvisory Vote on Named Executive Officer Compensation
Stockholders approved, by advisory vote, the 2016 compensation of
our named executive officers as set forth in the Proxy Statement.
The voting results on this proposal were as follows:
For
Against
Abstain
Broker Non-Votes
59,036,898
3,570,593
34,610
16,835,634
Proposal ThreeRatification of Appointment of Independent
Registered Public Accounting Firm
Stockholders ratified the appointment of Ernst Young LLP as Junos
independent registered public accounting firm for the fiscal year
ending December 31, 2017. The voting results on this proposal
were as follows:
For
Against
Abstain
79,336,094
101,349
40,292


About Juno Therapeutics, Inc. (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

An ad to help with our costs